Skip to content
Disclosery

Ally Bridge Group (NY) LLC

Follow

13F filer, CIK 1822947, NEW YORK, NY

Ally Bridge Group (NY) LLC reported $123,814,181 across 27 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-18. Its ten largest share positions make up 65.16% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-227559

Period
2026-03-31
Reported value
$124M
Holdings
27
Top 10 weight
65.16%
New
14
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CMPSnew+1,045,000$5.78M
TARSnew+80,859$5.67M
CTMXnew+900,000$4.23M
PRAXadded+12,928$4.17M
CATXnew+926,557$3.86M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ATAIBECKLEY INCexited-1,713,105-$7.01M
IVAreduced-754,700-$4.19M
ABVXreduced-36,288-$4.04M
TSHAexited-457,132-$2.51M
EWTXreduced-34,000-$1.07M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001193125-26-227559, largest first. % of portfolio is the value over $100,656,896, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 73,185 shares; 2024Q4: 44,982 shares; 2025Q1: 95,582 shares; 2025Q2: 80,880 shares; 2025Q3: not reported; 2025Q4: 19,882 shares; 2026Q1: 32,810 shares 32,810$10.6M10.5%+12,928Timeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,655,500 shares; 2026Q1: 1,655,500 shares 1,655,500$9.97M9.91%0Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 87,629 shares; 2025Q1: 120,449 shares; 2025Q2: 178,819 shares; 2025Q3: 302,483 shares; 2025Q4: 168,029 shares; 2026Q1: 200,000 shares 200,000$6.7M6.65%+31,971Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,785,000 shares; 2026Q1: 2,818,459 shares 2,818,459$6.26M6.22%+1,033,459Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,485,000 shares; 2025Q3: 1,026,382 shares; 2025Q4: not reported; 2026Q1: 1,045,000 shares 1,045,000$5.78M5.74%newTimeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 321,898 shares; 2024Q4: 173,144 shares; 2025Q1: 127,932 shares; 2025Q2: 121,182 shares; 2025Q3: 70,778 shares; 2025Q4: not reported; 2026Q1: 80,859 shares 80,859$5.67M5.64%newTimeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 724,000 shares; 2025Q3: 549,182 shares; 2025Q4: 413,625 shares; 2026Q1: 766,974 shares 766,974$5.52M5.49%+353,349Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 249,339 shares; 2026Q1: 414,219 shares 414,219$5.26M5.23%+164,880Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 187,695 shares; 2024Q4: 83,176 shares; 2025Q1: 102,650 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 195,000 shares; 2026Q1: 161,000 shares 161,000$5.07M5.04%-34,000Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 915,000 shares; 2025Q4: 397,895 shares; 2026Q1: 660,375 shares 660,375$4.78M4.75%+262,480Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 900,000 shares 900,000$4.23M4.2%newTimeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 745,300 shares 745,300$4.14M4.11%-754,700Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 341,739 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 926,557 shares 926,557$3.86M3.84%newTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 70,000 shares; 2026Q1: 33,712 shares 33,712$3.75M3.73%-36,288Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 418,416 shares; 2024Q4: 445,259 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 166,959 shares 166,959$3.68M3.65%newTimeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 202,124 shares 202,124$3.63M3.61%newTimeline
CAPRCAPRICOR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 113,899 shares 113,899$3.46M3.44%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 817,939 shares; 2025Q1: 817,939 shares; 2025Q2: 817,939 shares; 2025Q3: 817,939 shares; 2025Q4: 817,939 shares; 2026Q1: 817,939 shares 817,939$2.82M2.8%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,325,000 shares 1,325,000$2.23M2.21%newTimeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 526,315 shares 526,315$1.8M1.79%newTimeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 210,525 shares 210,525$1.47M1.46%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
SLNOSOLENO THERAPEUTICS INC COMput200,000$6.7Mnew
CMPXCOMPASS THERAPEUTICS INC COMcall1,000,000$5.29Mnew
QUREUNIQURE NV SHScall300,000$4.91M+100,000
MAZEMAZE THERAPEUTICS INC Stockcall100,000$2.98Mnew
REPLREPLIMUNE GROUP INC COMMON STOCKcall246,900$1.89M-953,100
KPTIKARYOPHARM THERAPEUTICS INC COMMON STOCKcall250,000$1.39Mnew

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CMPSCOMPASS PATHWAYS PLC1,100,000$7.59Mcall
ATAIBECKLEY INCATAIBECKLEY INC1,713,105$7.01Mshares
EWTXEDGEWISE THERAPEUTICS INC250,000$6.2Mput
TSHATAYSHA GENE THERAPIES INC500,000$2.75Mcall
TSHATAYSHA GENE THERAPIES INC457,132$2.51Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-227559 base2026-05-18acceptance time not in the bulk data set